A one-year, open-label trial demonstrated that weekly subcutaneous administration of Immunoglobulin Subcutaneous 20% (IGSC 20%) is effective for treating Primary Immunodeficiency (PI).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.